| Ruby Singh, DO | |
|
9961 Sierra Ave, Fontana, CA 92335-6720 | |
| (909) 427-3910 | |
| Not Available |
| Full Name | Ruby Singh |
|---|---|
| Gender | Female |
| Speciality | Family Medicine - Geriatric Medicine |
| Location | 9961 Sierra Ave, Fontana, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083766463 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QG0300X | Family Medicine - Geriatric Medicine | 20A9435 (California) | Primary |
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Between 17-21 October 2009, the 39th annual conference of the Society of Neuroscience drew some 30,500 people to the great city of Chicago, which was more balmy than windy for the occasion. Your Alzforum reporters have been busy roaming the halls, buttonholing scientists for their comments on the presentations, and putting together reports on the most significant advances.
Pharmacyclics, Inc. today announced that it has entered into stock purchase agreements with various institutional investors for the sale of approximately 6,150,000 shares of its common stock in a registered direct offering at $6.51 per share, the closing price on June 15, 2010.
Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.
A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers.
The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer, today announced the release of its Staging Atlas in Thoracic Oncology as a downloadable application for iPad, iPhone, Android or BlackBerry.
› Verified 8 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
Between 17-21 October 2009, the 39th annual conference of the Society of Neuroscience drew some 30,500 people to the great city of Chicago, which was more balmy than windy for the occasion. Your Alzforum reporters have been busy roaming the halls, buttonholing scientists for their comments on the presentations, and putting together reports on the most significant advances.
Pharmacyclics, Inc. today announced that it has entered into stock purchase agreements with various institutional investors for the sale of approximately 6,150,000 shares of its common stock in a registered direct offering at $6.51 per share, the closing price on June 15, 2010.
Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.
A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers.
The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer, today announced the release of its Staging Atlas in Thoracic Oncology as a downloadable application for iPad, iPhone, Android or BlackBerry.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ruby Singh, DO 10990 San Diego Mission Rd, San Diego, CA 92108-2417 Ph: (909) 427-3910 | Ruby Singh, DO 9961 Sierra Ave, Fontana, CA 92335-6720 Ph: (909) 427-3910 |
News Archive
Between 17-21 October 2009, the 39th annual conference of the Society of Neuroscience drew some 30,500 people to the great city of Chicago, which was more balmy than windy for the occasion. Your Alzforum reporters have been busy roaming the halls, buttonholing scientists for their comments on the presentations, and putting together reports on the most significant advances.
Pharmacyclics, Inc. today announced that it has entered into stock purchase agreements with various institutional investors for the sale of approximately 6,150,000 shares of its common stock in a registered direct offering at $6.51 per share, the closing price on June 15, 2010.
Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.
A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers.
The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer, today announced the release of its Staging Atlas in Thoracic Oncology as a downloadable application for iPad, iPhone, Android or BlackBerry.
› Verified 8 days ago
Robert M. Theal, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Todd A. Westra, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Pushkar Chand, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-5000 | |
Huy Phan, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-5000 | |
Dr. Yolandie Mccoskey, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9985 Sierra Ave, Fontana, CA 92335 Phone: 909-427-2049 | |
William J. Delo, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
John R. Sharpe Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 |